Literature DB >> 27708864

Evaluation of arterial stiffness with plasma GGT levels and pulse wave velocity measurement in patients with FMF.

Filiz Yılmaz1, Sena Ulu1, Önder Akcı2, Ahmet Ahsen1, Kasım Demir1, Şeref Yüksel1.   

Abstract

OBJECTIVE: Pulse wave velocity (PWV) is a non-invasive technique used to evaluate the arterial elasticity, which is an early indicator of atherosclerosis. Lately, gamma glutamyl transferase (GGT) is considered a determiner of arterial stiffness (AS). In this study, we aimed to evaluate the relationship between GGT levels and AS with PWV in patients with Familial Mediterranean fever (FMF).
MATERIAL AND METHODS: The study was conducted with 60 patients with FMF and 40 controls. Genetic analysis of the patients were performed. AS was assessed by PWV and, after the measurement of PWV, the presence of AS was determined.
RESULTS: Mean PWV values and AS frequency were significantly higher in patients with FMF compared with the control group (p<0.001 and p=0.004, respectively). Mean GGT levels of FMF patients were higher than in the control group but the difference was not statistically different. In the correlation analysis, PWV and AS were positively correlated with FMF (r=0349, p<0.001; r=0.435, p<0.001, respectively). FMF duration and FMF were associated with GGT (r=0.300, p=0.02; r=0199, p=0.047, respectively).
CONCLUSION: Increased PWV values in FMF patients may indicate arterial stiffness. These patients may be followed closely with PWV as an early indicator of atherosclerosis. Therefore, the cardiovascular risk can be determined in the early stages of disease and it may be possible to take necessary precautions.

Entities:  

Keywords:  Familial Mediterranean fever; arterial stiffness; gamma glutamyl transferase; pulse wave velocity measurement

Year:  2014        PMID: 27708864      PMCID: PMC5042255          DOI: 10.5152/eurjrheum.2014.003

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  22 in total

1.  Acute phase response and evolution of familial Mediterranean fever.

Authors:  M Tunca; G Kirkali; M Soytürk; S Akar; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  1999-04-24       Impact factor: 79.321

2.  The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function.

Authors:  Alma Cypiene; Aleksandras Laucevicius; Algirdas Venalis; Jolanta Dadoniene; Ligita Ryliskyte; Zaneta Petrulioniene; Milda Kovaite; Jonas Gintautas
Journal:  Clin Rheumatol       Date:  2008-07-25       Impact factor: 2.980

Review 3.  Inflammation-induced thrombosis: mechanisms, disease associations and management.

Authors:  Kenan Aksu; Ayhan Donmez; Gokhan Keser
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Validated methods for assessment of subclinical atherosclerosis in rheumatology.

Authors:  György Kerekes; Pál Soltész; Michael T Nurmohamed; Miguel A Gonzalez-Gay; Maurizio Turiel; Edit Végh; Yehuda Shoenfeld; Iain McInnes; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2012-02-21       Impact factor: 20.543

5.  Prevalence of ischemic heart disease in patients with familial Mediterranean fever.

Authors:  P Langevitz; A Livneh; L Neumann; D Buskila; J Shemer; D Amolsky; M Pras
Journal:  Isr Med Assoc J       Date:  2001-01       Impact factor: 0.892

6.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

7.  Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF.

Authors:  Ali Akdogan; Meral Calguneri; Bunyamin Yavuz; E Bengi Arslan; Umut Kalyoncu; Levent Sahiner; Omer Karadag; Ihsan Ertenli; Sedat Kiraz; Kudret Aytemir; Deniz Akata; Lale Tokgozoglu; Ali Oto
Journal:  J Am Coll Cardiol       Date:  2006-11-09       Impact factor: 24.094

8.  Increased pulse wave velocity and shortened pulse wave propagation time in young patients with rheumatoid arthritis.

Authors:  Mustafa Yildiz; Mehmet Soy; Turhan Kurum; Gultac Ozbay
Journal:  Can J Cardiol       Date:  2004-09       Impact factor: 5.223

9.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.

Authors:  A Duzova; A Bakkaloglu; N Besbas; R Topaloglu; S Ozen; F Ozaltin; Y Bassoy; E Yilmaz
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

10.  Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.

Authors:  H J Lachmann; B Sengül; T U Yavuzşen; D R Booth; S E Booth; A Bybee; J R Gallimore; M Soytürk; S Akar; M Tunca; P N Hawkins
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

View more
  4 in total

Review 1.  Familial Mediterranean fever and atherosclerosis in childhood and adolescence.

Authors:  Olga Vampertzi; Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Rheumatol Int       Date:  2019-11-08       Impact factor: 2.631

2.  Assessment of vascular damage in children and young adults with Familial Mediterranean Fever.

Authors:  Olga Vampertzi; Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Nikolaos Koletsos; Sofia Alataki; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Rheumatol Int       Date:  2021-11-05       Impact factor: 2.631

3.  Does Familial Mediterranean Fever Provoke Atherosclerosis in Children? Evaluation of Arterial Stiffness and Serum Endocan Levels.

Authors:  Serkan Türkuçar; Kaan Yıldız; Tuncay Küme; Ceyhun Açarı; Hatice Adıgüzel Dundar; Balahan Makay; Mustafa Kır; Erbil Ünsal
Journal:  Clin Rheumatol       Date:  2021-04-04       Impact factor: 2.980

4.  The relation of novel cardiovascular risk parameters in patients with familial Mediterranean fever.

Authors:  Mustafa Kozan; Zeynep Tugba Ozan; Vahit Demir; Hüseyin Ede
Journal:  JRSM Cardiovasc Dis       Date:  2019-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.